Name: MarketsandMarkets Biomarker and Companion Diagnostics Conference-East Coast Edition
Start: 2023-06-22
End: 2023-06-23
Location: Hilton Boston Logan Airport

EVENT OVERVIEW

Leveraging next gen technologies beyond conventional biomarker drug discovery!

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 22nd - 23rd June 2023 at Hilton Boston Logan Airport, Boston, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

Commercialization of CDx
Proteomics and Genomics based Biomarkers
Biomarker Drug Discovery and Assay Development
Multiplex Companion Diagnostics and Regulatory Guidelines
Design of clinical trials in CDx
Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Pathology
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development
Personalized Medicine
Immunology Biomarkers

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 09:05
Opening Remarks from the Chairman Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	09:05 - 09:10
Role of Biospecimen science in Clinical Biomarkers: Lessons Learned Lokesh Agrawal , Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH	09:10 - 09:45
Clinical Biomarker Validation and Assay Development
Personalized approach for identifying and tracking Molecular residual disease in Solid tumor Xinyuan Ma (Max), Translational Medicine Scientist, Biomarker & CDx Services, Burning Rock Dx	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:00
Accelerating your Biomarker Flywheel; Challenges and Opportunities Sarah Kehoe, Senior Director, Clinical Insights, Danaher Diagnostics	11:00 - 11:35
Unlocking the Power of Liquid Biopsy: Harnessing Tumor Fraction for Precision Monitoring and Treatment Planning Geoff Oxnard, Senior Vice President, Clinical Development, Foundation Medicine Christine Petersen, Associate Director, Biopharma Business Development, Foundation Medicine	11:35 - 12:10
Challenges and Opportunities in Discovering CDx Biomarkers Beyond Oncology Liling Warren, Senior Director, Translational Statistics, Teva Pharmaceuticals	12:10 - 12:45
Lunch and Poster Presentation \| One-to-One Networking Meetings	12:45 - 13:45
Role of Biomarkers in Personalized Medicine
Precision Oncology Centric Development of Antibody Drug Conjugates Rakesh Dixit, CEO, Bionavigen	13:45 - 14:20
Identification of New Targets and Precision Medicines through Single Molecule Tracking in Live Cells Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	14:20 - 14:55
Current State of Oncology Innovation Ben Freeberg, Founder, Managing Partner, Oncology Ventures	14:55 - 15:30
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:30 - 16:20
AI-enabled EEG biomarkers for CNS drug discovery Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic	16:20 - 16:55
Biomarkers in gene editing therapies for sickle cell disease Priya S. Chockalingam, Vice President, Head of Clinical Bioanalytics & Translational Sciences, Beam Therapeutics	16:55 - 17:25
Closing Remarks from the Chairman Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	17:25 - 17:25
End of Day 1 followed by Drinks Reception and Networking	17:25 - 17:25

Registration	08:15 - 09:00
Welcome note from MarketsandMarkets	09:00 - 09:05
Opening Remarks from the Chairman	09:05 - 09:10
Realizing the Promise of Precision Medicine: Companion Diagnostic Opportunity and Challenges Jason Simon, CDx Strategy Leader, Regeneron Pharmaceuticals	09:10 - 09:45
From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization
Assessing clinical and pharmacodynamic data in a phase I/Ib study with hetIL15 (NIZ985) and in combination with anti-PD1 (PDR001) in patients with solid tumors Nadia Hassounah, Principal Scientist, Novartis	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:00
Panel Discussion: Opportunities and challenges to integrate biomarker in clinical trial development process Hong Wang, Statistical Biomarker Leader, Sanofi Rakesh Dixit, CEO, Bionavigen Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic Sarah Kehoe, Senior Director, Clinical Insights, Danaher Diagnostics	11:00 - 11:40
From Brain to Blood: PRISM-Dx, Advancing Diagnostics Bradlee Heckmann, Co-Founder, CSO, Asha Therapeutics	11:40 - 12:15
Individualized Immunotherapy: ctDNA Monitoring Provides Real-time Signal of Clinical Benefit in Cancer Patients Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	12:15 - 12:50
Clinical Applications of Biomarkers in Cancer and Neurology
Lunch and Poster Presentation \| One-to-One Networking Meetings	12:50 - 13:50
A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection Carly Campbell, Principal Scientist, Translational Science & Diagnostics, Bicycle Therapeutics	13:50 - 14:25
Design of a comprehensive liquid biopsy assay to monitor real-time anti-tumor response in patients receiving an individualized neoantigen cancer vaccine Desiree Schenk, Principal Scientist, Gritstone Oncology	14:25 - 15:00
Closing Remarks from the Chairperson Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	15:00 - 15:05
End of Conference	15:05 - 15:05